Cell type-associated traits map for the [Braga_2020_lung_Lymphatic][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [Braga_2020_lung_Lymphatic]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 5.00e-2 | 1.74e-2 |
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 1.00e-2 | 2.52e-2 |
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 1.00e-4 | 4.33e-2 |
ADHD | Attention Deficit Hyperactivity Disorder | MTC | Middeldorp | 2016 | NA | 17666 | 5.00e-2 | 3.32e-2 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 2.10e-2 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-2 | 1.14e-2 |
Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 5.00e-2 | 3.11e-2 |
Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 1.00e-2 | 3.28e-2 |
Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-2 | 7.94e-3 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 4.73e-2 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 1.00e-2 | 1.26e-2 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 1.00e-3 | 5.83e-3 |
Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 5.00e-2 | 2.39e-2 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 4.07e-3 |
Anthropometric Extremes | Extreme Waist Hip Ratio | MTC | Berndt | 2013 | 4774 | 5481 | 5.00e-2 | 2.23e-2 |
Anthropometric Extremes | Extreme Waist Hip Ratio | MTC | Berndt | 2013 | 4774 | 5481 | 1.00e-2 | 1.29e-2 |
Anthropometrics Sex Stratified | Hip Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-4 | 4.36e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-3 | 2.37e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 1.00e-2 | 4.23e-2 |
Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-2 | 1.65e-2 |
Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 1.35e-2 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 5.00e-2 | 4.29e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.48e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 8.33e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.74e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.05e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.33e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 2.89e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.70e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.13e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 2.10e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 2.48e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 2.89e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.31e-3 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 1.00e-2 | 2.77e-2 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 5.00e-2 | 1.67e-2 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-2 | 4.75e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 2.49e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 1.35e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 1.36e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-3 | 4.43e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 1.05e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 4.65e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 5.00e-2 | 1.46e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 1.27e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7381 | 1.00e-3 | 2.02e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7399 | 5.00e-2 | 2.25e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7399 | 1.00e-2 | 2.54e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 2.97e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 1.35e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 7.41e-3 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 5.00e-2 | 8.69e-3 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 3.02e-3 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-3 | 2.25e-3 |
Facial Shape | Mod11 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 3.86e-2 |
Facial Shape | Mod14 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 6.90e-4 |
Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.48e-2 |
Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.89e-2 |
Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.45e-2 |
Facial Shape | Mod29 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.32e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 7.77e-5 |
Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.85e-2 |
Facial Shape | Mod46 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.43e-3 |
Facial Shape | Mod48 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 9.69e-3 |
Facial Shape | Mod49 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.85e-2 |
Facial Shape | Mod50 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.91e-2 |
Facial Shape | Mod51 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.87e-3 |
Facial Shape | Mod51 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.60e-2 |
Facial Shape | Mod56 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.66e-2 |
Facial Shape | Mod56 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.79e-2 |
Facial Shape | Mod59 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.06e-2 |
Facial Shape | Mod59 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.16e-3 |
Facial Shape | Mod60 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.21e-2 |
Forced Expiratory Volume | Forced Expiratory Volume | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 1.72e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 3.59e-2 |
Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 1.00e-3 | 1.55e-2 |
Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 5.00e-2 | 2.32e-2 |
Glycemic Traits BMI Corrected | Fasting Insulin Interaction With BMI | MTC | Manning | 2012 | NA | 51750 | 5.00e-2 | 3.39e-2 |
Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-2 | 1.76e-2 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 2.11e-2 |
Insulin Secretion | Insulin Secretion Rate Adjusted For BMI | MTC | Wood | 2017 | NA | 527 | 1.00e-2 | 2.31e-2 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 3.01e-3 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 7.50e-3 |
Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 5.00e-2 | 3.53e-2 |
Ischaemic Stroke | Small Vessel Disease | MTC | Traylor | 2012 | 2275 | 12285 | 1.00e-2 | 2.77e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 1.30e-3 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 1.34e-2 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 3.15e-2 |
Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 5.65e-3 |
Loneliness | Loneliness | MTC | Gao | 2017 | NA | 6924 | 5.00e-2 | 2.81e-2 |
Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 4.17e-2 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 3.17e-2 |
Stroke (ischemic) | Small Vessel Stroke | MTC | Traylor | 2017 | 1894 | 62004 | 1.00e-2 | 3.49e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 3.67e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 3.70e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 4.10e-4 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 3.36e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-5 | 9.07e-3 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-2 | 3.33e-2 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-3 | 4.70e-2 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-4 | 3.89e-2 |
Sleep | Sleep time to least active 5 hours | ETC | Jones | 2019 | NA | 85205 | 5.00e-2 | 3.29e-2 |
Sleep | Sleep time to least active 5 hours | ETC | Jones | 2019 | NA | 85205 | 1.00e-2 | 3.99e-2 |
Sleep | Sleep time to least active 5 hours | ETC | Jones | 2019 | NA | 85205 | 1.00e-3 | 2.69e-2 |
Sleep | Sleep time to least active 5 hours | ETC | Jones | 2019 | NA | 85205 | 1.00e-4 | 2.13e-2 |
Facial attractiveness | Facial attractiveness, female raters | ETC | Hu | 2019 | NA | 3928 | 5.00e-2 | 4.34e-2 |
MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 5.00e-2 | 1.52e-2 |
Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 1.00e-2 | 9.36e-3 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 6.87e-3 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 2.65e-2 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.22e-2 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 4.70e-3 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 1.91e-2 |
Parasubiculum volume | Parasubiculum volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.32e-2 |
Parasubiculum volume | Parasubiculum volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.21e-3 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-3 | 4.52e-2 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 3.55e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 1.71e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 2.45e-3 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 5.00e-2 | 3.55e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-4 | 3.56e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT3) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.64e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.38e-2 |
Occipital lobe volume | Occipital lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-4 | 2.58e-2 |
Occipital lobe volume | Occipital lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-5 | 3.40e-2 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-3 | 3.71e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 4.68e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 2.31e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-3 | 6.84e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 3.89e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-3 | 6.50e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 1.24e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 3.33e-3 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 1.22e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-3 | 3.95e-2 |
Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 5.00e-2 | 4.66e-2 |
Uterine fibroids | Uterine fibroids | ETC | Gallagher CS | 2019 | 20,406 | 223,918 | 1.00e-4 | 1.44e-2 |
BMI by age | BMI at 8 months old | ETC | Helgeland O | 2019 | NA | 7,197 | 1.00e-4 | 1.16e-2 |
BMI by age | BMI at 1.5 years old | ETC | Helgeland O | 2019 | NA | 6,800 | 1.00e-4 | 3.86e-2 |
BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 1.00e-2 | 4.02e-2 |
BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 1.00e-3 | 2.09e-2 |
Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-4 | 1.58e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 2.03e-5 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 2.99e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 1.92e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-4 | 1.20e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 1.81e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 3.19e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 1.65e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-2 | 1.08e-3 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-3 | 3.02e-2 |
Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-5 | 4.60e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 2.16e-4 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 2.23e-6 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 1.67e-4 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 4.88e-4 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 6.35e-5 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-3 | 1.65e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-4 | 3.64e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-2 | 2.01e-2 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 1.00e-2 | 2.70e-2 |
COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 5.00e-2 | 7.16e-3 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.